Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
复制标题
DOI：
10.3390/v13050893
复制
发表时间：
2021-05-12
期刊：
影响因子：
--
通讯作者：
Holbrook MR
中科院分区：
文献类型：
--
作者：
Bennett RS;Postnikova EN;Liang J;Gross R;Mazur S;Dixit S;Kocher G;Yu S;Georgia-Clark S;Gerhardt D;Cai Y;Marron L;Lukin VV;Holbrook MR
随着严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行的扩大，很明显，有效检测康复患者血液中中和抗体的存在对于开发基于血浆的治疗方法至关重要。为了满足对SARS-CoV-2高质量中和试验的需求，对先前建立的中东呼吸综合征冠状病毒（MERS-CoV）荧光还原中和试验（FRNA）进行了修改和优化。SARS-CoV-2 FRNA通过使用高容量成像系统提供了大量感染细胞的定量评估。由于这种方法，以及它不涉及主观解释的事实，该测定比其他中和测定更有效和更准确。此外，为单个平板和特定供试威尔斯孔设定稳健验收标准的能力为该试验提供了进一步的严格性。这种灵活的适应性有利于使用多种病毒变种。截至2021年2月，SARS-CoV-2 FRNA已用于筛查超过5000个样本，包括急性和恢复期血浆或血清样本以及治疗性抗体治疗，以检测SARS-CoV-2中和滴度。
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expanded, it was clear that effective testing for the presence of neutralizing antibodies in the blood of convalescent patients would be critical for development of plasma-based therapeutic approaches. To address the need for a high-quality neutralization assay against SARS-CoV-2, a previously established fluorescence reduction neutralization assay (FRNA) against Middle East respiratory syndrome coronavirus (MERS-CoV) was modified and optimized. The SARS-CoV-2 FRNA provides a quantitative assessment of a large number of infected cells through use of a high-content imaging system. Because of this approach, and the fact that it does not involve subjective interpretation, this assay is more efficient and more accurate than other neutralization assays. In addition, the ability to set robust acceptance criteria for individual plates and specific test wells provided further rigor to this assay. Such agile adaptability avails use with multiple virus variants. By February 2021, the SARS-CoV-2 FRNA had been used to screen over 5000 samples, including acute and convalescent plasma or serum samples and therapeutic antibody treatments, for SARS-CoV-2 neutralizing titers.
登录
查看更多内容
DOI：
10.1111/tme.12746
发表时间：
2021-06
期刊：
Transfusion medicine (Oxford, England)
影响因子：
--
作者：
Harvala H;Robb ML;Watkins N;Ijaz S;Dicks S;Patel M;Supasa P;Wanwisa D;Liu C;Mongkolsapaya J;Bown A;Bailey D;Vipond R;Grayson N;Temperton N;Gupta S;Ploeg RJ;Bolton J;Fyfe A;Gopal R;Simmonds P;Screaton G;Thompson C;Brooks T;Zambon M;Miflin G;Roberts DJ
通讯作者：
Roberts DJ
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
8.9
作者：
Huang C;Soleimani J;Herasevich S;Pinevich Y;Pennington KM;Dong Y;Pickering BW;Barwise AK
通讯作者：
Barwise AK
影响因子：
17.1
作者：
Luke, Thomas;Wu, Hua;Frieman, Matthew B.
通讯作者：
Frieman, Matthew B.
影响因子：
13.2
作者：
Sun, Baoqing;Feng, Ying;Chen, Ling
通讯作者：
Chen, Ling